Cargando…
Anti-angiogenesis target therapy for advanced osteosarcoma
Osteosarcomas (OS), especially those with metastatic or unresectable disease, have limited treatment options. The greatest advancement in treatments occurred in the 1980s when multi-agent chemotherapy, including doxorubicin, cisplatin, high-dose methotrexate, and, in some regimens, ifosfamide, was d...
Autores principales: | Xie, Lu, Ji, Tao, Guo, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562076/ https://www.ncbi.nlm.nih.gov/pubmed/28656259 http://dx.doi.org/10.3892/or.2017.5735 |
Ejemplares similares
-
Current research progress in targeted anti‐angiogenesis therapy for osteosarcoma
por: Liu, Yun, et al.
Publicado: (2021) -
Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma
por: Shaikh, Atik Badshah, et al.
Publicado: (2016) -
Endothelial Tip Cells in Ocular Angiogenesis: Potential Target for Anti-Angiogenesis Therapy
por: Siemerink, Martin J., et al.
Publicado: (2013) -
Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer
por: Eskander, Ramez N., et al.
Publicado: (2014) -
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)